Celcuity Inc. Common Stock (CELC)
Celcuity Inc. (CELC) is a biotechnology company focused on developing personalized cancer therapies through its innovative molecular and cellular analysis platform. The company utilizes its proprietary diagnostic technology to identify specific patient subgroups, enabling targeted treatments and improving clinical outcomes. Celcuity aims to translate complex biological data into actionable insights for better cancer treatment strategies.
Company News
Celcuity announced promising Phase 3 trial results for gedatolisib, a multi-target PAM inhibitor for advanced breast cancer, demonstrating significant improvements in progression-free survival and response rates compared to standard treatment.
Several biotech companies are developing innovative cancer treatments, with promising clinical trial results in various cancer types, focusing on immunotherapy and personalized medicine approaches.
Celcuity (CELC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The clinical-stage biotech announced the pricing of a secondary stock offering.